News und Analysen

Axsome Therapeutics' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over

A look at the facts will often reveal businesses that are poised for future growth and/or show no signs of slowing down. The stocks for these types of businesses tend to be particularly valuable to

There are several healthcare companies with market caps in the hundreds of billions. However, there isn't one among this group that is approaching the $1 trillion mark just yet. There are four

At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. It even has the added bonus of an attractive dividend yield of 3.7%. But there are some

Shares of Shockwave Medical (NASDAQ: SWAV) were up 10.69% early Tuesday afternoon after the Centers for Medicare and Medicaid Services (CMS) unveiled a proposed rule that detailed new payment codes

Shares of TG Therapeutics (NASDAQ: TGTX) were up by 18% as of mid-afternoon Tuesday after reports that the biotech's multiple sclerosis therapy Briumvi would have better-than-expected sales in its

Tilray Brands (NASDAQ: TLRY) shook up the cannabis sector with its third-quarter fiscal 2023 earnings report last night. But it wasn't the results that many were focused on, as both Tilray and

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the

Some corporate buyouts come as a total shock. Others aren't surprising in the least. I think you can include Tilray Brands' (NASDAQ: TLRY) planned acquisition of Hexo (NASDAQ: HEXO) in the latter